Innate Pharma (IPHA) Competitors $2.24 -0.02 (-0.88%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$2.19 -0.05 (-2.01%) As of 02/21/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends IPHA vs. ANAB, KURA, CRMD, ABUS, PHAR, IMTX, ORIC, RAPP, SEPN, and PGENShould you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include AnaptysBio (ANAB), Kura Oncology (KURA), CorMedix (CRMD), Arbutus Biopharma (ABUS), Pharming Group (PHAR), Immatics (IMTX), ORIC Pharmaceuticals (ORIC), Rapport Therapeutics (RAPP), Septerna (SEPN), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry. Innate Pharma vs. AnaptysBio Kura Oncology CorMedix Arbutus Biopharma Pharming Group Immatics ORIC Pharmaceuticals Rapport Therapeutics Septerna Precigen AnaptysBio (NASDAQ:ANAB) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, community ranking, media sentiment, earnings, analyst recommendations, risk, profitability and valuation. Is ANAB or IPHA more profitable? Innate Pharma has a net margin of 0.00% compared to AnaptysBio's net margin of -289.75%. Innate Pharma's return on equity of 0.00% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets AnaptysBio-289.75% -287.94% -37.25% Innate Pharma N/A N/A N/A Does the media refer more to ANAB or IPHA? In the previous week, AnaptysBio had 6 more articles in the media than Innate Pharma. MarketBeat recorded 8 mentions for AnaptysBio and 2 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 1.21 beat AnaptysBio's score of 0.13 indicating that Innate Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Innate Pharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer ANAB or IPHA? AnaptysBio received 326 more outperform votes than Innate Pharma when rated by MarketBeat users. Likewise, 66.19% of users gave AnaptysBio an outperform vote while only 58.97% of users gave Innate Pharma an outperform vote. CompanyUnderperformOutperformAnaptysBioOutperform Votes37266.19% Underperform Votes19033.81% Innate PharmaOutperform Votes4658.97% Underperform Votes3241.03% Do analysts recommend ANAB or IPHA? AnaptysBio presently has a consensus price target of $36.20, indicating a potential upside of 94.44%. Innate Pharma has a consensus price target of $11.50, indicating a potential upside of 413.39%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Innate Pharma is more favorable than AnaptysBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AnaptysBio 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.73Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do institutionals and insiders believe in ANAB or IPHA? 0.2% of Innate Pharma shares are held by institutional investors. 33.7% of AnaptysBio shares are held by insiders. Comparatively, 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has stronger valuation & earnings, ANAB or IPHA? Innate Pharma has higher revenue and earnings than AnaptysBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnaptysBio$17.16M33.02-$163.62M-$6.08-3.06Innate Pharma$66.71M2.81-$8.19MN/AN/A SummaryInnate Pharma beats AnaptysBio on 9 of the 15 factors compared between the two stocks. Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPHA vs. The Competition Export to ExcelMetricInnate PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$189.46M$3.12B$5.85B$9.15BDividend YieldN/A1.56%4.76%3.85%P/E RatioN/A10.3116.5114.19Price / Sales2.81327.11450.0276.60Price / CashN/A168.8538.0134.95Price / Book3.253.687.644.63Net Income-$8.19M-$71.72M$3.18B$245.69M7 Day Performance15.46%-2.46%-1.95%-2.68%1 Month Performance27.64%-0.25%-0.23%-2.16%1 Year Performance-12.84%-12.31%16.69%12.90% Innate Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPHAInnate Pharma3.0108 of 5 stars$2.24-0.9%$11.50+413.4%-7.8%$189.46M$66.71M0.00220News CoverageGap UpANABAnaptysBio3.77 of 5 stars$21.22+10.0%$37.45+76.5%-27.0%$645.73M$17.16M-3.49100High Trading VolumeKURAKura Oncology4.4041 of 5 stars$8.28flat$27.13+227.6%-58.7%$643.85MN/A-3.51130CRMDCorMedix1.325 of 5 stars$10.48+0.4%$15.67+49.5%+211.7%$635.90M$12.26M-12.9430News CoveragePositive NewsABUSArbutus Biopharma1.6623 of 5 stars$3.29-0.3%$5.50+67.2%+18.9%$623.42M$18.14M-7.6590PHARPharming Group2.9186 of 5 stars$9.13+3.2%$27.00+195.7%-19.7%$621.19M$285.75M-35.12280Positive NewsGap UpIMTXImmatics1.6069 of 5 stars$5.05-0.8%$16.67+230.0%-61.7%$602.77M$58.44M-7.65260ORICORIC Pharmaceuticals4.5393 of 5 stars$8.36+1.1%$18.71+123.9%-25.6%$589.97MN/A-4.6480Earnings ReportAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeRAPPRapport Therapeutics1.8127 of 5 stars$15.90+0.8%$35.00+120.1%N/A$581.62MN/A0.00N/AUpcoming EarningsSEPNSepterna2.177 of 5 stars$12.96+12.2%$43.67+236.9%N/A$575.42MN/A0.00N/AAnalyst DowngradeAnalyst RevisionNews CoverageGap UpPGENPrecigen3.9524 of 5 stars$1.96-1.0%$7.00+257.1%+34.5%$574.03M$6.22M-3.56190Gap Up Related Companies and Tools Related Companies ANAB Alternatives KURA Alternatives CRMD Alternatives ABUS Alternatives PHAR Alternatives IMTX Alternatives ORIC Alternatives RAPP Alternatives SEPN Alternatives PGEN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IPHA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
